How does Melphalan HCl kill cancer cells?
Melphalan HCl is an alkylating drug that attaches to cancer cell DNA and breaks it apart, stopping the cells from dividing and growing. It works best when combined with stem cell transplant or other chemotherapy drugs like bortezomib [1][3].
Melphalan damages cancer DNA by forming cross-links—like putting a lock on the cell's instruction manual. In multiple myeloma trials, melphalan combined with stem cell transplant produces complete remission in 40–50% of newly diagnosed patients [1]. High-dose melphalan (200 mg/m²) followed by stem cell rescue is the gold standard for transplant-eligible patients.
Inside your bone marrow, melphalan enters cancer cells and binds to their DNA strands. This breaks the cell's ability to copy itself and triggers cell death (apoptosis). The drug also activates immune cells to recognize and attack remaining myeloma cells [3].
The trade-off is that melphalan also damages healthy bone marrow cells, causing low blood counts for 2–3 weeks. That's why you need stem cell transplant to rescue your marrow and why your oncologist monitors your white blood cells, platelets, and hemoglobin closely [1].
Ask your oncologist: 'Will I get melphalan as a single high dose with stem cell transplant, or as a lower weekly dose?' This determines your recovery timeline and side effect intensity. Write down the exact dose and schedule before your first infusion.